Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,496 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Loculated or Non-draining Malignant Pleural Effusions
Interventions
Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Drug
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hypertriglyceridemia, Cardiovascular Disease
Interventions
Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
89
States / cities
Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more
Conditions
Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic, Dissociative Disorders
Interventions
sertraline, CBT-ip, Combined (sertraline + CBT-ip), Standard Care
Drug · Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Stanford, California • Cincinnati, Ohio • Providence, Rhode Island
Conditions
HIV Infections
Interventions
Zidovudine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Conditions
Chronic Low Back Pain, Musculoskeletal Pain
Interventions
intermittent theta burst stimulation, LoveYourBrain Yoga Program
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
22 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma
Interventions
Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Corticospinal Activation for Improved Walking Function

NCT03237234
Conditions
Spinal Cord Injuries
Interventions
Motor Skill Training, Transcranial direct current stimulation (tDCS)
Other · Device
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Spencer's Technique on Shoulder Function

NCT06447493
Conditions
Shoulder
Interventions
Osteopathic Manipulative Treatment-Spencer's Technique (Modified), Rest
Other
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Auburn, Alabama
Completed Not applicable Interventional Results available

Integrated vs Sequential Treatment for PTSD and Addiction

NCT01211106
Conditions
PTSD, Substance Addiction
Interventions
Prolonged Exposure, Motivational Enhancement Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Conditions
Ewing Sarcoma, Colorectal Adenocarcinoma
Interventions
INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
12 Years to 85 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
Conditions
HIV Preexposure Prophylaxis
Interventions
ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Block for Pain Control With Osmotic Dilator Placement

NCT02354092
Conditions
Abortion Late, Pain
Interventions
Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control
Procedure · Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
San Diego, California
Conditions
MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Interventions
S095029, pembrolizumab 200 mg (KEYTRUDA ®)
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Ocala, Florida • Noblesville, Indiana • Houston, Texas
Conditions
Urothelial Carcinoma
Interventions
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more
Conditions
Colorectal Cancer
Interventions
cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
Dietary Supplement · Genetic · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Completed Phase 1 Interventional Results available

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

NCT02193347
Conditions
Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
Interventions
PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Temozolomide
Biological · Drug
Lead sponsor
Katy Peters, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Smoking Cessation, Stress, Sleep Disturbance, Nausea
Interventions
Varenicline Pill, Hydroxyzine Pill
Drug
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Sub-Acute and Chronic Low Back Pain
Interventions
Chiropractic care, Multidisciplinary, integrative care
Other
Lead sponsor
Northwestern Health Sciences University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bloomington, Minnesota